ARDS (Aridis Pharmaceuticals) 14-Day RSI: 41.43 (As of Jul. 04, 2026)


ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals 14-Day RSI?

Aridis Pharmaceuticals ARDS -99.00% 12 14-Day RSI is 41.43 as of Jul. 04, 2026. GuruFocus rates ARDS with a GF Score™ of 12/100.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-07-04), Aridis Pharmaceuticals's 14-Day RSI is 41.43.

The industry rank for Aridis Pharmaceuticals's 14-Day RSI or its related term are showing as below:

ARDS's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 49.99 vs ARDS: 41.43

Aridis Pharmaceuticals  (OTCPK:ARDS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Aridis Pharmaceuticals 14-Day RSI Related Terms

ARDS vs ARTL, REVB, FWBI: 14-Day RSI Comparison

For the Biotechnology subindustry, Aridis Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aridis Pharmaceuticals 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's 14-Day RSI falls into.


ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
14-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals  (OTCPK:ARDS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 14-Day RSI →
What does a 14-Day RSI of 41.43 mean?
Aridis Pharmaceuticals (ARDS) has a 14-Day RSI of 41.43 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' 14-Day RSI too high?
Aridis Pharmaceuticals' current 14-Day RSI is 41.43. The Biotechnology industry median 14-Day RSI is 49.99. Aridis Pharmaceuticals' value of 41.43 is 17.1% below this industry median. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' 14-Day RSI compare to ARTL and REVB?
Aridis Pharmaceuticals' 14-Day RSI of 41.43 can be compared against companies in the Biotechnology industry. The industry median 14-Day RSI is 49.99. Aridis Pharmaceuticals' value of 41.43 is 17.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aridis Pharmaceuticals's current 14-Day RSI of 41.43 is 17.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aridis Pharmaceuticals and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aridis Pharmaceuticals's current 14-Day RSI is 41.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current 14-Day RSI of 41.43. The current 14-Day RSI is 41.43 and 17.1% below the Biotechnology industry median of 49.99. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current 14-Day RSI is 41.43 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price